Parkinson's disease (PD) is a progressive neurodegenerative disease that causes a debilitating movement disorder. Although most cases of PD appear to be sporadic, rare Mendelian forms have provided tremendous insight into disease pathogenesis. Accumulating evidence suggests that impaired mitochondria underpin PD pathology. In support of this theory, data from multiple PD models have linked Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) and parkin, two recessive PD genes, in a common pathway impacting mitochondrial health, prompting a flurry of research to identify their mitochondrial targets. Recent work has focused on the role of PINK1 and parkin in mediating mitochondrial autophagy (mitophagy); however, emerging evidence casts parkin and PINK1 as key players in multiple domains of mitochondrial health and quality control.
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Parkinson's disease is a mitochondrial disease of aging PD is a common neurodegenerative disease of complex etiology marked by the insidious onset of a constellation of characteristic movement symptoms, including resting tremor, bradykinesia, rigidity, and difficulty initiating movement. These movement symptoms are attributed to the relatively selective loss of dopamine-producing neurons in the substantia nigra pars compacta (SNc). Over the past 30 years, basic and clinical research points to mitochondrial compromise as a central or contributing factor to PD pathogenesis [1] [2] [3] .
Although 90% of PD cases are considered sporadic, a few Mendelian forms of PD discovered over the past 15 years are now thought to comprise at least 10% of disease burden [4, 5] . Mutations in genes encoding Leucine-rich repeat kinase 2 (LRRK2), a-synuclein, parkin, PINK1, and DJ-1 among others lead, with varying penetrance, to the development of PD. Their discovery has brought substantial genetic tools to bear on the problem of PD pathogenesis. Years of studying pathogenic variants of these genes has yielded evidence tying each to mitochondrial health [2], but perhaps none more so than the autosomal-recessive PD (AR-PD)-linked PINK1 and parkin [1] [2] [3] 6 ]. Here, we review the evolving body of evidence characterizing the role of PINK1 and parkin as key regulators of mitochondrial quality control.
PINK1 and Parkin in PD
Mutations in the parkin gene are the most common cause of autosomal recessive PD [4, 5, 7] . The gene encodes a 465-amino acid E3 ubiquitin ligase capable of mediating monoor polyubiquitination using different ubiquitin linkages via lysine 27, 29, 48, and 63 of ubiquitin. To date, more than 100 pathogenic parkin mutations disrupt the E3 ligase activity of the protein, either directly or by altering the solubility or stability of the protein, leading to dopaminergic (DA) cell death [4, 5, 8] . Moreover, recent evidence from postmortem PD brain samples and mouse models suggest that parkin is inactivated by post-translational modifications. These include oxidation, nitrosylation, addition of dopamine, and phosphorylation by c-Abl, an important stress-activated nonreceptor tyrosine kinase that is activated in sporadic PD brains and in animal models of PD (reviewed in [9, 10] ). These findings imply that parkin dysfunction may have a broader role in sporadic PD [9] . Parkin seems to mediate its effects in multiple cellular compartments, including the cytosol, synaptic terminals, mitochondria, and nucleus. Crystallization of parkin suggests that it exists in an autoinhibited state with the requirement that it undergoes structural changes to be fully active [11, 12] . How parkin is activated is not known, but translocation to the mitochondria or association with its substrate, E2 conjugating enzyme or CHIP, are likely to be key activators [12, 13] .
The PINK1 (or PARK6) gene was first connected to PD by linkage analysis of consanguineous families with early-onset AR-PD [4, 14] . Loss of PINK1 is the second most common cause of AR-PD. The gene encodes a mitochondrial targeted serine/threonine kinase and loss of this kinase function is associated with the development of PD. Recent studies show that mitochondrial-localized PINK1 is mainly situated in the outer mitochondrial membrane (OMM) with its
